[go: up one dir, main page]

WO2003015667A1 - Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie - Google Patents

Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie Download PDF

Info

Publication number
WO2003015667A1
WO2003015667A1 PCT/US2002/024646 US0224646W WO03015667A1 WO 2003015667 A1 WO2003015667 A1 WO 2003015667A1 US 0224646 W US0224646 W US 0224646W WO 03015667 A1 WO03015667 A1 WO 03015667A1
Authority
WO
WIPO (PCT)
Prior art keywords
implant
body portion
scleral
intra
elongated
Prior art date
Application number
PCT/US2002/024646
Other languages
English (en)
Other versions
WO2003015667A8 (fr
Inventor
David Castillejos
Original Assignee
David Castillejos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Castillejos filed Critical David Castillejos
Priority to BR0215382-3A priority Critical patent/BR0215382A/pt
Priority to EP02768411A priority patent/EP1418864A4/fr
Priority to CA002455120A priority patent/CA2455120A1/fr
Priority to MXPA04001076A priority patent/MXPA04001076A/es
Priority to IL16003702A priority patent/IL160037A0/xx
Priority to JP2003520429A priority patent/JP4346438B2/ja
Priority to KR10-2004-7001249A priority patent/KR20040024873A/ko
Publication of WO2003015667A1 publication Critical patent/WO2003015667A1/fr
Publication of WO2003015667A8 publication Critical patent/WO2003015667A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/147—Implants to be inserted in the stroma for refractive correction, e.g. ring-like implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Definitions

  • the disclosed device relates to a scleral implant. More particularly it relates to a device which is implanted in the sclera of the eye for the treatment of excess intraocular pressure which frequently accompanies Glaucoma and for the treatment of presbyopia or loss of accommodation of the eye.
  • Glaucoma is an e ⁇ e disease wherein the patient gradually loses sight. Such vision loss is caused by damage to the pptic nerve which acts like an electric cable and communicates images from the eye to the brain.1 High intraocular pressure frequently accompanies Glaucoma and is one of the main causes of the nerve damage causing this vision loss. It is thought that increased intraocular pressure is caused when the eye's drainage canals become clogged over time. The intraocular pressure rises to levels causing damage because the correct amount of fluid can't drain out of the eye in the normal fashion. If this excess intraocular pressure is not detected and treated, it can cause a gradual loss of vision Such a vision loss in some cases occurs over a long period of time. However, in some cases of glaucoma the eye pressure usually rises very fast. It is thought that this happens when the eye drainage canals are blocked or covered over, Like the clog in a sink when something is covering the drain
  • Drugs are frequently used on cases where intraocular pressure slowly builds and frequently work well. In
  • Another sight rek ted problem affecting patients is that of Presbyopia which is a vision condition in which the crystalline lens f a p nt'g ey t ⁇ g g jt ⁇ flexibility.
  • Tft ⁇ lOS ⁇ Of flexibility makes it difficult for a person to focus on close objects. While Presbyopia may seem to occur suddenly once the patient discovers the problem, it is generally accepted that the cause of the sight loss is actual loss of flexibility of the lens which takes place over a number of years and usually becomes noticeable in the early to mid-forties.
  • Treatment to help you compensate for presbyopia includes prescription reading glasses, bifocals, contact lenses, and laser surgery.
  • corrective lenses can be inconvenient to the wearer and laser surgery to the lens of the eye carries with it the inherent risk to the eyesight itself if a mistake is made.
  • U.S. Patent No. 6,280,468 discloses a scleral prosthesis for treatment of presbyopia and other eye disorders.
  • Schachar teaches the placement of a prostheses in a plurality of pockets slightly smaller than the implant, circumferentially around the pupil, to exert an outward pressure on the sclera thereby restoring the working distance of the ciliary muscle allowing the patient relief from presbyopia.
  • Schachar is oriented circumferentially around the pupil or front of the eye and lacks an anchoring means to hold the implants in proper position in the sclera over the long term which can result in shifting of the implant reducing or eliminating its effectiveness. Further, the use of tunnels smaller than the implant tends to cause broken implants.
  • Schachar also lacks a drug delivery means from the implant. Still further, actual dismounting of the implant can occur which would require removal from the eye especially if it pierces the outside surface of the eye when shifting in position. Additionally, the circumferential placement of the implants is not as effective at encouraging internal drainage and reduction of intraocular pressure.
  • U.S. Patent No. 6,102,045 discloses a method and apparatus for lowering intraocular pressure of the eye.
  • Nordquist is a filtering implant which extends into the anterior chamber of the eye through an opening in the limbus cornea.
  • Nordquist lacks the ability to correct presbyopia that a sclera-mounted device provides and because of its delicate positioning and communication directly with the anterior chamber Nordquist is harder to position correctly. It also lacks the ability to infuse drugs to the eye and the provision of direct communication between the anterior chamber and the exterior regions of the eye increases the risk of infection to the anterior chamber.
  • U.S. Patent No. 6,079,417 discloses a method and device for reshaping the cornea to change its topography.
  • Fugo lacks the ability to increase the drainage from the eye interior to lower intraocular pressure.
  • Fugo also is designed to mount directly into the cornea layer of the eye.
  • Such a device should be insertable into the eye in a relatively easy procedure for a trained surgeon. Such a device and procedure should avoid the more delicate structures of the eye and should also avoid communicating internal eye structures directly with the exterior of the eye to prevent infection. Such a device would provide additional utility by through the optional ability to provide a drug delivery system from the implant directly to the eye. Still further, the device implanted by this method should be dimensioned with an anchor structure to insure that the implant stays properly positioned in perpetuity thereby alleviating the need for replacement or removal caused by dislocatable implants and maintaining a fixed correction of vision.
  • the above problems, and others are overcome by the herein disclosed method and intra- sclera implant for the treatment of glaucoma and presbyopia.
  • the method of insertion of the implants requires incisions be made radially in the anterior sclera. A plurality of such incisions are made radially and only into the sclera with the current best number of incisions being four, with one incision in each quadrant of the eye.
  • one implant is positioned within the space of each of the incisions.
  • the scleral incision is then closed by opposition or using suture or other means of closure of the incision to urge the scleral flap toward the surface of the eye from where it was detached and reattach it to the sclera.
  • the implant is currently best formed in a unitary construction and formed of a material that is inert when in contact with body tissue.
  • Favored materials include one or a combination of materials from a group including hydroxiapartite, silicone, polymethylmethacrylate, acrylic, and tantalum.
  • the unitary body of the implant can optionally be serrated or have one or a plurality of apertures running through to contact scleral tissue and anchor it. Additionally, the body of the implant can also be impregnated with a drug which thereafter would be slowly delivered into the tissue of the eye or have an internal reservoir or coating of a slowly disburseable drug that can be modulated for dose and time frame to allow for long term delivery of medication to the eye and body of the patient, from the implant.
  • Yet another object of this invention is the provision of a method and apparatus for eye surgery that may be used to treat presbyopia as well as rising intraocular pressure.
  • Figure 1 depicts the placement of a plurality of implants radially in four quadrants of the eye and the steps of the method to do so.
  • Figure 2 shows the implant and its placement in the scleral layer of the eye.
  • Figure 3 depicts a preferred embodiment of the implant showing anchors and optional coating.
  • Figure 4 depicts another preferred embodiment of the device having an internal reservoir for holding a drug to be communicated to the exterior.
  • Figure 5 depicts another preferred embodiment of the device showing anchors about the exterior.
  • Figure 6 depicts another preferred embodiment of the device showing a round body and anchors extending from the surface.
  • figure 1 depicts the preferred location and steps in the operative method for the placement of
  • the eye 12 In its basic structure the eye 12 consists of a globe having an outer coat, a middle layer
  • the outer coat is made up of a tough fibrous, white layer - the sclera 16,
  • the conjunctiva 18 which communicates with the conjunctiva 18 which is a mucous membrane that lines the inner surfaces of the eyelids and folds back to cover the front surface of the eyeball, except for the
  • the middle layer contains
  • the inner layer is the light seeing layer or retina 24.
  • Presbyopia is a vision condition in which the
  • lens 26 loses some of its flexibility, or the zonules 30 become elongated making it harder for the
  • Intraocular pressure in the eye 12 is caused by a build up of fluid in the anterior chamber
  • Canal of Schlemm which is the sewer system duct of the eye getting rid of excess fluid
  • anterior chamber 36 and posterior chamber 38 are anterior chamber 36 and posterior chamber 38.
  • incisions 32 expose the sclera 16 wherein next, in each conjunctival incision 32, a radial incision
  • an implant device 10 is positioned within the space formed by the
  • the radial incision 34 may be closed using a means of closure
  • implant device 10 radially oriented away from the cornea 20 might be done in other fashions
  • the device 10 is placed radially oriented and surrounded by the sclera in a formed cavity and the
  • the device 10 is properly placed to improve both the vision and fluid drainage of the patient.
  • implant device 10 may be removed in the reverse order.
  • the implant device 10 used in combination with the surgical method, in the current best
  • the implant device is formed of a material that is inert when in contact with body tissue.
  • a tightening or tensioning of the sclera 16 layer is provided when the
  • radial incision 34 is closed and the scleral flap 21 is sutured or otherwise rejoined with the sclera 16 and stretched over the implant device 10 during closure.
  • Favored materials include one or a
  • the implant device 10 has body portion 46 and a means to anchor the device in radial
  • anchors 48 protruding from the body portion 46. Other means to anchor the device
  • the device 10 can be provided with a means to
  • This drug delivery system can be provided by one or a combination of micro
  • the material from which the device 10 is produced can be any material from which the device 10 is produced.
  • the material from which the device 10 is produced can be any material from which the device 10 is produced.
  • the dosage and delivery time can be modulated by adjusting the amount of communication
  • hypodermic needle 27 which would pierce the sclera 16 and refill the reservoir 60 through one of
  • Figure 6 depicts the device 10 with a body 46 that is round or barrel shaped rather than the cube or rectangular shape of figures 3-5.
  • the body 46 would work well in either configuration so long as one of the noted anchoring means projects from it to anchor the device 10 in the radial cavity. While the curved projections 52 are shown on all sides, it may be beneficial in some cases to omit them from one side for smooth transition of the scleral flap 21 over the implant device 10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Surgery (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un implant intra-scléral (10) et un procédé d'implantation utilisé dans le traitement de la pression intraoculaire et de la presbyopie. Cet implant comprend une partie corps (46) pourvue de parties saillantes (48) qui permettent de fixer le dispositif dans une cavité (19) formée dans la paroi sclérale (16) de l'oeil (12). Une fonction d'administration de médicament est éventuellement prévue pour permettre la diffusion à long terme de médicaments dans les tissus qui entourent l'implant.
PCT/US2002/024646 2001-08-03 2002-08-02 Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie WO2003015667A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0215382-3A BR0215382A (pt) 2001-08-03 2002-08-02 Método e implante intra-esclerótico para o tratamento de glaucoma e presbiopia
EP02768411A EP1418864A4 (fr) 2001-08-03 2002-08-02 Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie
CA002455120A CA2455120A1 (fr) 2001-08-03 2002-08-02 Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie
MXPA04001076A MXPA04001076A (es) 2001-08-03 2002-08-02 Metodo e implante intraescleral para tratamiento de glaucoma y presbicia.
IL16003702A IL160037A0 (en) 2001-08-03 2002-08-02 Method and intra sclera implant for treatment of glaucoma and presbyopia
JP2003520429A JP4346438B2 (ja) 2001-08-03 2002-08-02 緑内障および老眼の治療のための方法および強膜内インプラント
KR10-2004-7001249A KR20040024873A (ko) 2001-08-03 2002-08-02 녹내장과 노안 치료를 위한 공막내 이식장치와 그 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31002701P 2001-08-03 2001-08-03
US60/310,027 2001-08-03

Publications (2)

Publication Number Publication Date
WO2003015667A1 true WO2003015667A1 (fr) 2003-02-27
WO2003015667A8 WO2003015667A8 (fr) 2004-12-16

Family

ID=33510228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024646 WO2003015667A1 (fr) 2001-08-03 2002-08-02 Methode et implant intra-scleral pour le traitement du glaucome et de la presbyopie

Country Status (6)

Country Link
EP (1) EP1418864A4 (fr)
JP (1) JP4346438B2 (fr)
KR (1) KR20040024873A (fr)
CA (1) CA2455120A1 (fr)
IL (1) IL160037A0 (fr)
WO (1) WO2003015667A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133182A1 (fr) 2008-04-30 2009-11-05 Tesa Se Film de séparation en polyoléfine et son utilisation
AU2005338015B2 (en) * 2005-10-31 2010-05-13 Life Spring Biotech Co., Ltd. Scleral buckle band and method for making it
WO2010061207A1 (fr) * 2008-11-01 2010-06-03 University Of Dundee Dispositif de mesure de pression
WO2011155916A1 (fr) * 2010-06-11 2011-12-15 Damiano Richard E Dispositif d'amélioration pour la lecture pour prévenir et traiter la presbytie de l'œil
US8945038B2 (en) 2003-05-05 2015-02-03 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US9084662B2 (en) 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US9089392B2 (en) 2009-12-23 2015-07-28 Transcend Medical, Inc. Drug delivery devices and methods
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
US9351873B2 (en) 2003-11-14 2016-05-31 Transcend Medical, Inc. Ocular pressure regulation
US9398977B2 (en) 2006-01-17 2016-07-26 Transcend Medical, Inc. Glaucoma treatment device
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9763828B2 (en) 2009-01-28 2017-09-19 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10016301B2 (en) 2008-06-25 2018-07-10 Novartis Ag Ocular implant with shape change capabilities
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US10307292B2 (en) 2011-07-18 2019-06-04 Mor Research Applications Ltd Device for adjusting the intraocular pressure
EP3541323A4 (fr) * 2016-12-23 2020-08-05 Refocus Group, Inc. Prothèse sclérale à surface(s) dentelée(s) ou autre(s) destinée à être retenue dans un tissu scléral, destinée à traiter la presbytie
US12226525B2 (en) 2006-03-31 2025-02-18 Mati Therapeutics, Inc. Nasolacrimal drainage system implants for drug therapy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908298C (fr) * 2006-07-11 2017-10-03 Refocus Group, Inc. Prothese sclerale pour traiter la presbytie et d'autres troubles oculaires et des dispositifs et procedes correspondants
US8672870B2 (en) 2007-07-17 2014-03-18 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities
ES2523681T3 (es) * 2007-08-02 2014-11-28 Refocus Group, Inc. Prótesis escleral que tiene varillas transversales para tratar la presbicia y otros trastornos del ojo

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178604A (en) 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5558630A (en) * 1994-12-30 1996-09-24 Fisher; Bret L. Intrascleral implant and method for the regulation of intraocular pressure
US6079417A (en) 1999-03-23 2000-06-27 Fugo; Richard J. Method of altering the shape of the cornea of the eye
US6102045A (en) 1994-07-22 2000-08-15 Premier Laser Systems, Inc. Method and apparatus for lowering the intraocular pressure of an eye
US6280468B1 (en) 1997-10-08 2001-08-28 Ras Holding Corp Scleral prosthesis for treatment of presbyopia and other eye disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4946436A (en) * 1989-11-17 1990-08-07 Smith Stewart G Pressure-relieving device and process for implanting
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5968058A (en) * 1996-03-27 1999-10-19 Optonol Ltd. Device for and method of implanting an intraocular implant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178604A (en) 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US6102045A (en) 1994-07-22 2000-08-15 Premier Laser Systems, Inc. Method and apparatus for lowering the intraocular pressure of an eye
US5558630A (en) * 1994-12-30 1996-09-24 Fisher; Bret L. Intrascleral implant and method for the regulation of intraocular pressure
US6280468B1 (en) 1997-10-08 2001-08-28 Ras Holding Corp Scleral prosthesis for treatment of presbyopia and other eye disorders
US6079417A (en) 1999-03-23 2000-06-27 Fugo; Richard J. Method of altering the shape of the cornea of the eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1418864A4

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844462B2 (en) 2003-05-05 2017-12-19 Novartis Ag Internal shunt and method for treating glaucoma
US8945038B2 (en) 2003-05-05 2015-02-03 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US9351873B2 (en) 2003-11-14 2016-05-31 Transcend Medical, Inc. Ocular pressure regulation
US10226380B2 (en) 2003-11-14 2019-03-12 Novartis Ag Ocular pressure regulation
AU2005338015C1 (en) * 2005-10-31 2010-11-18 Life Spring Biotech Co., Ltd. Scleral buckle band and method for making it
AU2005338015B2 (en) * 2005-10-31 2010-05-13 Life Spring Biotech Co., Ltd. Scleral buckle band and method for making it
US12303430B2 (en) 2006-01-17 2025-05-20 Alcon Inc. Glaucoma treatment device
US9421130B2 (en) 2006-01-17 2016-08-23 Novartis Ag. Glaucoma treatment device
US11786402B2 (en) 2006-01-17 2023-10-17 Alcon Inc. Glaucoma treatment device
US9398977B2 (en) 2006-01-17 2016-07-26 Transcend Medical, Inc. Glaucoma treatment device
US9668917B2 (en) 2006-01-17 2017-06-06 Novartis Ag Drug delivery treatment device
US9084662B2 (en) 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US10905590B2 (en) 2006-01-17 2021-02-02 Alcon Inc. Glaucoma treatment device
US9789000B2 (en) 2006-01-17 2017-10-17 Novartis Ag Glaucoma treatment device
US12226525B2 (en) 2006-03-31 2025-02-18 Mati Therapeutics, Inc. Nasolacrimal drainage system implants for drug therapy
WO2009133182A1 (fr) 2008-04-30 2009-11-05 Tesa Se Film de séparation en polyoléfine et son utilisation
US10016301B2 (en) 2008-06-25 2018-07-10 Novartis Ag Ocular implant with shape change capabilities
GB2476762A (en) * 2008-11-01 2011-07-06 Univ Dundee Pressure measurement device
WO2010061207A1 (fr) * 2008-11-01 2010-06-03 University Of Dundee Dispositif de mesure de pression
GB2476762B (en) * 2008-11-01 2012-01-18 Univ Dundee Pressure measurement device
US11344448B2 (en) 2009-01-28 2022-05-31 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US10531983B2 (en) 2009-01-28 2020-01-14 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US9763828B2 (en) 2009-01-28 2017-09-19 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US11839571B2 (en) 2009-01-28 2023-12-12 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US12233004B2 (en) 2009-01-28 2025-02-25 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US9549846B2 (en) 2009-12-23 2017-01-24 Novartis Ag Drug delivery devices and methods
US9089392B2 (en) 2009-12-23 2015-07-28 Transcend Medical, Inc. Drug delivery devices and methods
WO2011155916A1 (fr) * 2010-06-11 2011-12-15 Damiano Richard E Dispositif d'amélioration pour la lecture pour prévenir et traiter la presbytie de l'œil
US10307292B2 (en) 2011-07-18 2019-06-04 Mor Research Applications Ltd Device for adjusting the intraocular pressure
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US10912676B2 (en) 2012-04-24 2021-02-09 Alcon Inc. Delivery system for ocular implant
US9907697B2 (en) 2012-04-24 2018-03-06 Novartis Ag Delivery system for ocular implant
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
EP3541323A4 (fr) * 2016-12-23 2020-08-05 Refocus Group, Inc. Prothèse sclérale à surface(s) dentelée(s) ou autre(s) destinée à être retenue dans un tissu scléral, destinée à traiter la presbytie

Also Published As

Publication number Publication date
CA2455120A1 (fr) 2003-02-27
JP4346438B2 (ja) 2009-10-21
JP2005508213A (ja) 2005-03-31
EP1418864A4 (fr) 2009-07-01
KR20040024873A (ko) 2004-03-22
WO2003015667A8 (fr) 2004-12-16
EP1418864A1 (fr) 2004-05-19
IL160037A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
US8267995B2 (en) Method and intra sclera implant for treatment of glaucoma and presbyopia
US20070027537A1 (en) Method and intra-sclera implant for treatment of glaucoma and presbyopia
US20070219632A1 (en) Method and intra-sclera implant for treatment of glaucoma and presbyopia
JP4346438B2 (ja) 緑内障および老眼の治療のための方法および強膜内インプラント
US10492948B2 (en) Glaucoma drainage shunts and methods of use
CA2493010C (fr) Dispositif de drainage uveoscleral
RU2650203C2 (ru) Устройства расширяющихся офтальмологических имплантатов
JP3088746B2 (ja) 緑内障インプラント
US7060094B2 (en) Accommodating zonular mini-bridge implants
US10342703B2 (en) Glaucoma drainage implant
JP2002541976A (ja) 緑内障を治療するためのステント装置および方法
WO1994002081A9 (fr) Implant oculaire permettant de soulager les symptomes du glaucome
MXPA04001076A (es) Metodo e implante intraescleral para tratamiento de glaucoma y presbicia.
RU2236201C2 (ru) Способ микродренирования при лечении глаукомы (варианты)
KR102844717B1 (ko) 안압 조절용 방수유출장치
HK1069524A (en) Method and intra sclera implant for treatment of glaucoma and presbyopia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 160037

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2455120

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047001249

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001076

Country of ref document: MX

Ref document number: 2003520429

Country of ref document: JP

Ref document number: 20028152166

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 120/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002768411

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002768411

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2003 UNDER (30) REPLACE "60/310,227" BY "60/310,027"

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)